



Lipomics and Cure Autism Now Collaborate on New Research

Results May Identify Autism Biomarkers Using Lipomic Profiling

WEST SACRAMENTO, California, Dec. 14, 2004 -- Lipomics Technologies, Inc., a privately held company that develops tools for assessing and understanding complex metabolic conditions using proprietary technologies for lipid metabolite analysis and interpretation, today announced that it has signed an agreement with Cure Autism Now for a new biomarker study in children with autism and related disorders. Results from this study may offer clues about the causes of autism and may lead to better therapeutics for this and other neurodevelopmental disorders.

Building on previous research, Lipomics will produce extensive lipomic profiles of children with autism, their siblings, and age-matched controls to identify metabolic signatures of the disorder. Samples analyzed in this study will be collected by Cure Autism Now's DNA repository—the Autism Genetic Resource Exchange (AGRE).

“Deficiencies of lipid metabolism could be related to some of the physiological symptoms found in autism,” said Clara Lajonchere, Ph.D., AGRE Program Director. “The data generated by Lipomics will contribute important new biological information to the growing body of research available to scientists worldwide through AGRE. The results may offer promising clues to understanding the causes of autism. Cure Autism Now hopes to replicate and extend its initial findings by using the expertise that Lipomics provides.”

“Autism is increasing in prevalence, but its causes and cures have remained elusive,” said Dr. Tom Anderson, president and CEO of Lipomics. “By applying our specialized knowledge and understanding of lipid biology, we hope to contribute valuable new understanding to the search for accurate diagnosis and effective treatment options.”

About Autism

Autism affects an estimated one in every 166 children in the United States. Autism is characterized by varying degrees of impairment in communication skills, social interactions, and restricted, repetitive and stereotyped patterns of behavior. Until recently, autism was considered a lifelong, incurable disorder. However, with early identification and intensive intervention and treatment, the outcomes of children with autism can be significantly improved.

About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms

for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at www.lipomics.com.

About Cure Autism Now

Cure Autism Now is a non-profit organization dedicated to promoting and funding autism research and accelerating the pace of scientific progress toward effective treatments and a cure for autism. The organization is the leading funder of biological research in autism, providing more than \$20 million for research grants, education, outreach and scientific resources, including the establishment and ongoing support of the Autism Genetic Resource Exchange (AGRE). Cure Autism Now has chapters in Los Angeles, Orange County and San Francisco, California; New Jersey, New York City, Chicago, Philadelphia, Houston, Seattle, Maryland/DC Area, and Honolulu. For more information about Cure Autism Now, go to www.cureautismnow.org.

###

EDITORIAL CONTACTS:

Sarina Chohan, Lipomics Technologies
(916) 371-7974
schohan@lipomics.com

Clara M. Lajonchere, Ph.D, CURE AUTISM NOW
AGRE Program Director
(323) 931.6577 x15

Agency Contact

Doug Forsyth, Alchymia Communications for Lipomics
(541) 482-8744
df@alchymiacomm.com